Home Stock

Stock Research: Astellas Pharma

Independent stock analysis through peer comparison: Get the 360° View as an objective basis for stock decision-making and explore the detailed ranks.

Astellas Pharma

TYO:4503 JP3942400007
85
  • Value
    96
  • Growth
    41
  • Safety
    Safety
    45
  • Combined
    81
  • Sentiment
    70
  • 360° View
    360° View
    85
Unlock
What factors are driving this 360° View?
Subscribe to View
Company Description

Astellas Pharma Inc. is a Japan-based pharmaceutical company focused on the research, development, manufacture, and sale of pharmaceutical products. The company operates in the pharmaceutical industry, with products including XTANDI, BETANIS, and MIRABETRIC. Astellas Pharma Inc. primarily operates in Japan. In the last fiscal year, the company had a market cap of $17,488 million, profits of $10,424 million, and revenue of $12,753 million, with 13,643 employees.

more

ANALYSIS: With an Obermatt 360° View of 85 (better than 85% compared with alternatives) for 2026, overall professional sentiment and financial characteristics for the stock Astellas Pharma are very positive. The 360° View is based on consolidating four consolidated indicators, with half the metrics below and half above average for Astellas Pharma. The consolidated Value Rank has an attractive rank of 96, which means that the share price of Astellas Pharma is on the lower side compared with the typical size in indicators such as revenues, profits, and invested capital. This means that the stock price is lower than for 96% of alternative stocks in the same industry. The consolidated Sentiment Rank has a good rank of 70, which means that professional investors are more optimistic about the stock than for 70% of alternative investment opportunities. But the consolidated Growth Rank has a low rank of 41, which means that the company exhibits below-average growth momentum when looking at financial metrics such as revenue, profit, invested capital growth, and stock returns. The consolidated Safety Rank has a riskier rank of 45, meaning the company has a riskier financing structure than 55 comparable companies when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. ...read more

more
Strongest Rank Analyst Opinions
Weakest Rank Dividend Yield
Country Japan
Industry Pharmaceuticals
Size X-Large
Website astellas.com
Index
TOPIX 100
Nikkei 225
Astellas Pharma stock price by TradingView. Not sourced by Obermatt.
Similar Add to Watchlist Similar See Similar Stocks
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 23-Jun-2026.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Value
Identifies how good a value the stock is.
Good Value Expensive
Combined
Consolidated view across Value, Growth, and Safety.
Good Tread Carefully
Growth
Shows a company's growth potential.
High Growth Tough Times
Sentiment
Shows what the market thinks of a stock.
Positive Sentiment Skepticism
Safety
Safety
Assesses how financially secure a company is.
Well-Financed High Leverage
360° View
360° View
Holistic stock analysis: all key non-/financial metrics
Good Watch Out

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
96 70 66 67
Growth
41 49 19 89
Safety
Safety
45 10 39 39
Sentiment
70 16 6 14
360° View
360° View
85 21 12 55
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Analyst Opinions
1 30 50 65
Opinions Change
50 23 15 50
Pro Holdings
n/a 40 16 18
Market Pulse
75 26 9 17
Sentiment
70 16 6 14
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
96 70 66 67
Growth
41 49 19 89
Safety Safety
45 10 39 39
Combined
81 35 33 76
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Price vs. Sales (P/S)
64 74 59 50
Price vs. Earnings (P/E)
77 42 58 80
Price vs. Book (P/B)
67 41 45 53
Dividend Yield
100 96 91 92
Value
96 70 66 67
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Revenue Growth
15 18 58 47
Profit Growth
35 67 55 79
Capital Growth
32 71 4 54
Stock Returns
97 42 27 85
Growth
41 49 19 89
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Leverage
39 17 59 48
Refinancing
22 4 7 21
Liquidity
88 34 72 72
Safety Safety
45 10 39 39

Similar Stocks

Discover high‑ranked alternatives to Astellas Pharma and broaden your portfolio horizons.

Brother Industries

TYO:6448
Country: Japan
Industry: Technology Hardware & Peripherals
Size: X-Large
Full Stock Analysis

Ushio

TYO:6925
Country: Japan
Industry: Electr. Components & Equipment
Size: Large
Full Stock Analysis

Nippon Electric Glass

TYO:5214
Country: Japan
Industry: Electronic Components
Size: Large
Full Stock Analysis

Resorttrust

TYO:4681
Country: Japan
Industry: Hotels, Resorts & Cruise Lines
Size: Large
Full Stock Analysis

Frequently Asked
Questions

With good value and positive sentiment, but low growth and risky financing, this combination is generally dangerous as debt requires growth to sustain it. Only investors with a strong belief in future growth potential and a high-risk tolerance should consider this stock.

Obermatt provides unbiased stock analysis as a completely independent third party. We have no conflicts of interest with individual stock titles. Our data-driven analysis is based on algorithms honed over twelve years, giving you analysis that is free from personal bias and conflicts of interest.

The 360° View Rank indicates a company's overall performance across all major financial and non-financial metrics tracked by Obermatt. A 360° View Rank of 75 means the company is more well-rounded than 75% of similar companies. A high score indicates that the company is strong across the board; it is attractively priced, growing sustainably, financially stable, and well-regarded by the market. Learn more.

Become an Obermatt subscriber and see all of the similar stocks here.

OTHER FEATURES

Use the Platform to its Fullest

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.

What Our Customers Say

See how Obermatt improved their investing:

Review us See More Google Reviews